Acesion Pharma's new approach to atrial fibrillation
Interviewee/Contributor
Morten Grunnet
Organisation
Acesion Pharma ApS
Research Directory
European biotechs mixed in quarter
Interviewee/ContributorWilliam EllingtonWhat Roche's takeover of Flatiron Health really means
Interviewee/ContributorTara RaveendranOrganisationShore CapitalInnate Pharma aims to regain leadership in IO
Interviewee/ContributorRobin DavisonOrganisationNew Science Global Healthcare FundAntibody-degrading enzyme enables transplants
Interviewee/ContributorEmanuel BjörneOrganisationHansa Medical ABMitochondrial quality control as potential therapy
Interviewee/ContributorPaul ThompsonOrganisationMission TherapeuticsBuilding a European capital market
Interviewee/ContributorWilliam EllingtonOrganisationEvernow Publishing LtdThe new complexity in clinical study protocols
Interviewee/ContributorShiva MemariOrganisationVertical KnowingCell therapy success and the competition for value
Interviewee/ContributorMiguel ForteOrganisationZelluna Immunotherapy ASWhy pharma is paying a premium for assets
Interviewee/ContributorTim Sturgeon and Martin GouldstoneOrganisationResults Healthcare